Invented at EPFL Lausanne, the eyeWatch is a microscopic drainage tube for glaucoma surgery equipped with a valve that can be adjusted with a magnet. Made of biocompatible materials, it reduces the post-operative risks associated with conventional surgery. It is thus the first device in the world allowing glaucoma surgery that can be modulated according to needs. Almost three years after its first implantation by Professor Mermoud at the Clinique de Montchoisi in Lausanne, its use continues to grow and international newspapers have already dedicated several articles to it. The first long-term results have recently been widely reported in the scientific literature. At the end of 2019, the eyeWatch received the CE marking (European conformity) which allows it to be marketed in European countries that recognize the label. This certification mark indicates that the health, safety and environmental protection standards are conform to the European Economic Area. In Switzerland, the Clinique de Montchoisi has exclusive rights.